Literature DB >> 6290390

Protection against lethal challenge of BALB/c mice by passive transfer of monoclonal antibodies to five glycoproteins of herpes simplex virus type 2.

N Balachandran, S Bacchetti, W E Rawls.   

Abstract

Monoclonal antibodies secreted by six hybridomas and recognizing antigenic sites on glycoproteins gC, gAB, gD, gE, and gF of herpes simplex virus type 2 were examined for their ability to protect BALB/c mice from lethal infection by the virus. Administration of monoclonal antibodies to individual glycoproteins intraperitoneally 3 h before footpad challenge with 10 times the 50% lethal dose of virus protected between 35 and 75% of the mice, except for one of two monoclonal antibodies recognizing antigens on gC. The antibodies did not neutralize virus in vitro and protected A/J mice deficient in the fifth component of complement as efficiently as complement-sufficient BALB/c mice. A good correlation was found between protection and titers of monoclonal antibodies assessed by antibody-dependent cell-mediated cytolysis. The results indicate that any of the glycoproteins can serve as antigens for a protective immune response. In addition, the data are compatible with protection being mediated by an antibody-dependent cell-mediated cytolysis mechanism.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6290390      PMCID: PMC347658          DOI: 10.1128/iai.37.3.1132-1137.1982

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  27 in total

1.  Role for cell-mediated immunity in the resistance of mice to subcutaneous herpes simplex virus infection.

Authors:  J E Oakes
Journal:  Infect Immun       Date:  1975-07       Impact factor: 3.441

2.  Postexposure serum prophylaxis of neonatal herpes simplex virus infection of mice.

Authors:  S Baron; M G Worthington; J Williams; J W Gaines
Journal:  Nature       Date:  1976-06-10       Impact factor: 49.962

3.  Pathogenesis of herpetic neuritis and ganglionitis in mice: evidence for intra-axonal transport of infection.

Authors:  M L Cook; J G Stevens
Journal:  Infect Immun       Date:  1973-02       Impact factor: 3.441

4.  Detection of cell-dependent cytotoxic antibody to cells infected with herpes simplex virus.

Authors:  S L Shore; A J Nahmias; S E Starr; P A Wood; D E McFarlin
Journal:  Nature       Date:  1974-09-27       Impact factor: 49.962

5.  Spread of herpes simplex virus in peripheral nerves.

Authors:  K Kristensson; E Lycke; J Sjöstrand
Journal:  Acta Neuropathol       Date:  1971       Impact factor: 17.088

6.  Antigenic differences between isolates of herpesvirus type 2.

Authors:  P Seth; W E Rawls; R Duff; F Rapp; E Adam; J L Melnick
Journal:  Intervirology       Date:  1974       Impact factor: 1.763

7.  Quantitation of antibodies to Herpes simplex virus types 1 and 2 by complement-dependent antibody lysis of infected cells.

Authors:  H McClung; P Seth; W E Rawls
Journal:  Am J Epidemiol       Date:  1976-08       Impact factor: 4.897

8.  Passive immunization in experimental Herpesvirus hominis infection of newborn mice.

Authors:  F Luyet; D Samra; A Soneji; M I Marks
Journal:  Infect Immun       Date:  1975-12       Impact factor: 3.441

9.  Mechanism of injury of virus-infected cells by antiviral antibody and complement: participation of IgG, F(ab')2, and the alternative complement pathway.

Authors:  L H Perrin; B S Joseph; N R Cooper; M B Oldstone
Journal:  J Exp Med       Date:  1976-05-01       Impact factor: 14.307

10.  Deficiency of the fifth component of complement in mice with an inherited complement defect.

Authors:  U R Nilsson; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1967-01-01       Impact factor: 14.307

View more
  84 in total

1.  Glycoprotein gI of pseudorabies virus promotes cell fusion and virus spread via direct cell-to-cell transmission.

Authors:  L Zsak; F Zuckermann; N Sugg; T Ben-Porat
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

2.  Prophylaxis and therapy of virulent encephalomyocarditis virus infection in mice by monoclonal antibodies. Brief report.

Authors:  F Vlaspolder; C A Kraaijeveld; R van Buuren; M Harmsen; B J Benaissa-Trouw; H Snippe
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

3.  Prevention and treatment of experimental herpes simplex virus encephalitis with human immune serum globulin.

Authors:  K S Erlich; R D Dix; J Mills
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

4.  Antiviral antibodies attenuate T-cell-mediated immunopathology following acute lymphocytic choriomeningitis virus infection.

Authors:  K E Wright; M J Buchmeier
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

5.  Acute and latent infection of mice immunised with HSV-1 ISCOM vaccine.

Authors:  M Erturk; T J Hill; C Shimeld; R Jennings
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

6.  Passive immune protection by herpes simplex virus-specific monoclonal antibodies and monoclonal antibody-resistant mutants altered in pathogenicity.

Authors:  G Kümel; H C Kaerner; M Levine; C H Schröder; J C Glorioso
Journal:  J Virol       Date:  1985-12       Impact factor: 5.103

7.  Antigenic variation (mar mutations) in herpes simplex virus glycoprotein B can induce temperature-dependent alterations in gB processing and virus production.

Authors:  S D Marlin; S L Highlander; T C Holland; M Levine; J C Glorioso
Journal:  J Virol       Date:  1986-07       Impact factor: 5.103

8.  Humanized antibodies for antiviral therapy.

Authors:  M S Co; M Deschamps; R J Whitley; C Queen
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-01       Impact factor: 11.205

9.  Immunogenicity of herpes simplex virus glycoproteins gC and gB and their role in protective immunity.

Authors:  J Glorioso; C H Schröder; G Kumel; M Szczesiul; M Levine
Journal:  J Virol       Date:  1984-06       Impact factor: 5.103

10.  Protection against lethal viral infection by neutralizing and nonneutralizing monoclonal antibodies: distinct mechanisms of action in vivo.

Authors:  L Lefrancois
Journal:  J Virol       Date:  1984-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.